Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Industry Speculating Tax Hike Will Delay Annual Revision Rollout to 2021
January 13, 2017
-
REGULATORY Chuikyo Industry, Doctor Reps in Discord over Scope of Price Review for Indication Expansions
January 12, 2017
-
BUSINESS Ariad Deal Is “Global Acquisition” Not Limited to US Market: Takeda CEO
January 11, 2017
-
REGULATORY Chuikyo to Kick Off Debates to Elaborate Pricing Revamp; 2 Industry Hearing Sessions Planned
January 11, 2017
-
BUSINESS Opdivo Gastric Cancer Filing Casts Cloud on Keytruda’s Sakigake Status
January 10, 2017
-
BUSINESS Takeda to Buy US Oncology Firm Ariad
January 10, 2017
-
REGULATORY MHLW to Regularly Compile Optimal Drug Use Guidelines from FY2017: Pharma Bureau Chief
January 6, 2017
-
REGULATORY From Regulatory Agency to Industry-Fostering Agency: Health Minister
January 5, 2017
-
REGULATORY Policymakers Rolling Up Their Sleeves to Embody Drug Pricing Overhaul
January 1, 2017
-
REGULATORY AMED Plans to Introduce Medical-Economic Viewpoints for Its R&D Support
December 28, 2016
-
BUSINESS 40 Billion Yen Sales for Oncology Business in FY2020 Achievable: Daiichi Sankyo
December 27, 2016
-
ORGANIZATION Novo’s Ole Moelskov Bech to Helm EFPIA Japan from January
December 26, 2016
-
BUSINESS Sumitomo Dainippon to Buy US Hematology Startup Tolero
December 22, 2016
-
BUSINESS Ono Slashes Opdivo Sales Outlook on 50% Price Cut
December 22, 2016
-
REGULATORY Quarterly Price Reviews for Indication-Added Drugs Likely to Get Underway in FY2017, Annual Scheme in FY2018: Officials
December 21, 2016
-
BUSINESS New Technologies to Cure Cancers, Help Reduce Medical Expenditure: Report
December 21, 2016
-
REGULATORY Four Ministers Map Out Basic Policy for Drug Pricing Revamp
December 21, 2016
-
REGULATORY Basic Policy for Drastic Reform of Drug Pricing System
December 20, 2016
-
BUSINESS Keytruda Gets NSCLC Nod Both in 1st-Line, 2nd-Line Settings
December 20, 2016
-
ACADEMIA New Lung Cancer Guidelines to Give Keytruda Grade A Recommendation as First-Line Treatment
December 19, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…